Steve Kubby Appointed CEO of International Endeavors (IDVV)


(NEW YORK)–International Endeavors Corporation (OTCMKTS: IDVV) stock rallied on the appointment of cannabis veteran Steve Kubby as new CEO of IDVV.

IDVV stock rallied on news that they would be moving into the biomedical aspect of cannabis pharmaceutical research, and had appointed cannabis veteran Steve Kubby as new CEO of the company.

The Company announced a deal with Kubby Cryogenics which Steve Kubby will immediately become CEO of International Endeavor Corporation (“IDVV”).

Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc., traded under the symbol (OTCMKTS:CBDS).

Mr. Kubby played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.

Biomedical Research

Kubby Cryogenics, along with IDVV, will look to patent medical grade cannabis strains that are genetically profiled to treating specific diseases.

The company will be acquiring licensing rights to patent new delivery systems in the future. Further, the company will continue with product development in their own proprietary Cryogenics line, which captures the highest medical value of any product known on the market today.

To accomplish these goals, Kubby Cryogenics has assembled a team of top Scientists and Geneticists to research and develop the strains for these Cryogenic Extract products.

Steve Kubby, the new CEO of International Endeavors commented, “We are very excited to partner with IEC, and anticipate bringing a new class of medicine to the market through our pure line of medical grade cannabis products featuring our patent pending Cryogenic process. We will create a dispensary system for legal medical cannabis states standardizing the patient centered, consultation approach while presenting an enticing line of Adult Use products featuring a patent pending menu of powerful strains and pure, all natural, solvent-less concentrate products.”

Cryogenics Medical Uses

Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.

About International Endeavors Corporation

International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases.


This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was not compensated as of the date of this alert for ongoing media advisory services. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Safe Harbor Statements:

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

High Risk

Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.